CN111135314A - Nano-composite for early diagnosis and treatment of gastric cancer and preparation method thereof - Google Patents
Nano-composite for early diagnosis and treatment of gastric cancer and preparation method thereof Download PDFInfo
- Publication number
- CN111135314A CN111135314A CN202010098157.8A CN202010098157A CN111135314A CN 111135314 A CN111135314 A CN 111135314A CN 202010098157 A CN202010098157 A CN 202010098157A CN 111135314 A CN111135314 A CN 111135314A
- Authority
- CN
- China
- Prior art keywords
- gastric cancer
- treatment
- nano
- composite
- early diagnosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002114 nanocomposite Substances 0.000 title claims abstract description 64
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 45
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 45
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 45
- 238000011282 treatment Methods 0.000 title claims abstract description 32
- 238000013399 early diagnosis Methods 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 229960004657 indocyanine green Drugs 0.000 claims abstract description 41
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 29
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 23
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 22
- 239000010410 layer Substances 0.000 claims abstract description 17
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 16
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract description 14
- 239000012792 core layer Substances 0.000 claims abstract description 8
- 229920001577 copolymer Polymers 0.000 claims abstract description 7
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical group CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000011258 core-shell material Substances 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- MOFVSTNWEDAEEK-UHFFFAOYSA-M indocyanine green Chemical compound [Na+].[O-]S(=O)(=O)CCCCN1C2=CC=C3C=CC=CC3=C2C(C)(C)C1=CC=CC=CC=CC1=[N+](CCCCS([O-])(=O)=O)C2=CC=C(C=CC=C3)C3=C2C1(C)C MOFVSTNWEDAEEK-UHFFFAOYSA-M 0.000 claims description 39
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 38
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 19
- 229940009456 adriamycin Drugs 0.000 claims description 18
- 238000004108 freeze drying Methods 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 16
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 12
- 238000000502 dialysis Methods 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 11
- 238000009210 therapy by ultrasound Methods 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000002390 rotary evaporation Methods 0.000 claims description 9
- 239000012153 distilled water Substances 0.000 claims description 7
- 150000001413 amino acids Chemical group 0.000 claims description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 4
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 2
- 108010038807 Oligopeptides Proteins 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims description 2
- 229930012538 Paclitaxel Natural products 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
- 229960004316 cisplatin Drugs 0.000 claims description 2
- 238000001816 cooling Methods 0.000 claims description 2
- 229960002949 fluorouracil Drugs 0.000 claims description 2
- 229960001592 paclitaxel Drugs 0.000 claims description 2
- 238000005086 pumping Methods 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 239000011148 porous material Substances 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 25
- 239000003814 drug Substances 0.000 abstract description 25
- 238000003384 imaging method Methods 0.000 abstract description 7
- 230000002776 aggregation Effects 0.000 abstract description 5
- 238000004220 aggregation Methods 0.000 abstract description 5
- 238000000799 fluorescence microscopy Methods 0.000 abstract description 4
- 230000009471 action Effects 0.000 abstract description 3
- 238000012377 drug delivery Methods 0.000 abstract description 3
- 201000011591 microinvasive gastric cancer Diseases 0.000 abstract description 3
- 238000010863 targeted diagnosis Methods 0.000 abstract description 3
- 125000003827 glycol group Chemical group 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 24
- 230000000052 comparative effect Effects 0.000 description 23
- 239000000243 solution Substances 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 239000000693 micelle Substances 0.000 description 11
- 230000008685 targeting Effects 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 9
- 239000002086 nanomaterial Substances 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000003917 TEM image Methods 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 238000005538 encapsulation Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 5
- 238000011068 loading method Methods 0.000 description 5
- 238000011580 nude mouse model Methods 0.000 description 5
- 241000699660 Mus musculus Species 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 238000002356 laser light scattering Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000003333 near-infrared imaging Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
- A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
- A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
- A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
- A61K49/0089—Particulate, powder, adsorbate, bead, sphere
- A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
- A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a nano-composite for early diagnosis and treatment of gastric cancer and a preparation method thereof. The nano composite has a core-shell structure formed by an amphiphilic copolymer, an inner core layer is formed by a distearoyl phosphatidyl ethanolamine fragment, an outer shell layer is formed by a polyethylene glycol fragment, near-indocyanine green and hydrophobic gastric cancer chemotherapy drugs are wrapped in the inner core layer, and the surface of the outer shell layer is connected with RGD short peptide. The nano-composite preparation integrates targeted gastric cancer treatment and fluorescence imaging tracing, can realize targeted aggregation on gastric cancer focus imaging, controls the release of drugs, increases the concentration of targeted site drugs and improves the action time of the drugs, and has wide application prospect in early gastric cancer targeted diagnosis and treatment and drug delivery.
Description
Technical Field
The invention relates to the technical field of high polymer materials and medical engineering, in particular to a nano-composite for early diagnosis and treatment of gastric cancer and a preparation method thereof.
Background
Gastric cancer is a common malignant tumor in China, the number of new cases is over 100 ten thousand per year, more than 80 percent of cases are diagnosed in middle and advanced stages, and the number of death cases is up to 70 ten thousand per year, so that diagnosis and treatment of gastric cancer and colorectal cancer become problems to be solved urgently. At present, the diagnosis of part of early lesions by an endoscope is difficult, the control of incisal margins under the endoscope is difficult, and the treatment of gastric cancer still generally adopts oral or injection anti-cancer chemotherapeutic drugs (chemotherapy) in clinic. However, the specific aggregation effect of the drug at the tumor site is poor, and an effective targeting technology is lacked, so that normal cells are attacked by the drug, and toxic and side effects are inevitably generated; and the treatment process and the imaging tracing or diagnosis cannot be carried out simultaneously, and the restraining effect on rapidly developing and metastatic tumors is limited. Therefore, there is an urgent need for developing a new technical means for gastric cancer diagnosis and treatment that integrates targeted therapy and imaging tracing.
Indocyanine green (ICG) is a tricarbocyanine dye that can be almost completely bound to plasma proteins in plasma and whole blood, and can be guaranteed to remain almost completely in blood vessels and not easily diffuse outward. Indocyanine green is a near-infrared imaging agent approved by the U.S. Food and Drug Administration (FDA) for clinical use at present, has an emission wavelength of 795-845 nm, has the characteristics of an amphiphilic structure, namely hydrophilicity and lipophilicity, and can be used as an excellent in-vivo tissue penetrating agent. The integrin is highly expressed on the surfaces of various tumor cells and tumor vascular endothelial cells, and is low expressed in normal cells and vascular cells, and the RGD molecule is a tripeptide sequence capable of being specifically combined with the integrin and is a hot molecule for tumor targeting research. A plurality of research results show that the RGD is connected with a fluorescent molecule or a radionuclide and has a certain tumor targeted imaging function, however, the RGD and the fluorescent molecule or radionuclide conjugate has small molecular weight, high metabolism speed in vivo and easy clearance, and poor targeting is caused. Therefore, the delivery of the fluorescent molecule and the RGD short peptide molecule to the tumor site using a carrier with good biocompatibility is an important issue facing the current gastric cancer diagnosis method.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide a nano-composite for early diagnosis and treatment of gastric cancer and a preparation method thereof, the nano-composite integrates targeted gastric cancer treatment and fluorescence imaging tracing, can realize targeted aggregation on gastric cancer focus imaging, simultaneously controls the release of drugs, increases the concentration of targeted site drugs and improves the action time of the drugs, and has wide application prospect in the aspects of early gastric cancer targeted diagnosis and treatment and drug delivery.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
a nano-composite for early diagnosis and treatment of gastric cancer has a core-shell structure formed by an amphiphilic copolymer, an inner core layer is formed by distearoyl phosphatidyl ethanolamine fragments, an outer shell layer is formed by polyethylene glycol fragments, indocyanine green and hydrophobic gastric cancer chemotherapeutic drugs are wrapped in the inner core layer, and the surface of the outer shell layer is connected with RGD short peptide.
According to the invention, fluorescent molecule indocyanine green is modified by using amphiphilic polymer, hydrophobic gastric cancer chemotherapy drugs are coated at the same time, RGD short peptide molecules are modified to synthesize a nano fluorescent probe, the purposes of integrating tumor treatment and fluorescence development are achieved by combining the passive targeting property of nano molecules, the active targeting property of RGD short peptide and the fluorescent molecule development, and a multifunctional targeting nano drug carrier system capable of effectively improving the diagnosis and treatment effects of gastric cancer is expected to be developed.
Preferably, the amphiphilic copolymer is distearoyl phosphatidyl ethanolamine-polyethylene glycol-maleimide; the hydrophobic gastric cancer chemotherapeutic drug comprises at least one of adriamycin, 5-fluorouracil, paclitaxel and cisplatin.
Preferably, the amphiphilic copolymer is distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide, more preferably, the molecular weight of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide is 2805.5, and an amphiphilic nano micelle can be formed.
The invention takes RGD short peptide (amino acid sequence is Arg-Gly-Asp) capable of targeting gastric cancer vascular endothelial cells as a target to prepare a polymer nano micelle carrier (DSPE-PEG-Mal), simultaneously assembles and compounds indocyanine green with the carrier through hydrophobic electrostatic interaction, finally adsorbs drug adriamycin in a hydrophobic inner core to synthesize drug-loaded micelle (DSPE-PEG/ICG/DOX-RGD), and constructs the nano compound for early diagnosis and treatment of gastric cancer.
The nano composite adopts a core-shell structure formed by amphiphilic copolymers, an inner core layer is formed by hydrophobic distearoyl phosphatidyl ethanolamine segments, an outer shell layer is formed by hydrophilic polyethylene glycol segments, hydrophobic gastric cancer chemotherapeutic drugs and ICG are wrapped in the inner core layer, and RGD polypeptide molecules are connected to the hydrophilic surface of the micelle through chemical bonds. The nano-composite can realize the imaging of target aggregation at the focus of the gastric cancer, and simultaneously control the release of the drug, and has wide application prospect in the aspects of target diagnosis and treatment of the gastric cancer and drug slow release.
Preferably, the nanocomposite comprises the following components in parts by weight: 5-20 parts of distearoyl phosphatidyl ethanolamine-polyethylene glycol-maleimide, 1-5 parts of indocyanine green, 0.5-1 part of hydrophobic gastric cancer chemotherapy drug and one part per million to one hundred thousand parts of RGD oligopeptide. The components can form a nano composite drug-loaded micelle in which indocyanine green and hydrophobic gastric cancer chemotherapeutic drugs are coated on the nano composite hydrophobic layer, and the RGD short peptide is connected to the hydrophilic section.
Preferably, the particle size of the nano-composite is 50-200 nm.
Preferably, the amino acid sequence of the RGD short peptide is Arg-Gly-Asp.
The invention also provides a preparation method of the nano-composite for early diagnosis and treatment of gastric cancer, which comprises the following steps:
(1) adding indocyanine green into tetrahydrofuran, adding distearoyl phosphatidyl ethanolamine-polyethylene glycol-maleimide and hydrophobic gastric cancer chemotherapeutic drugs, mixing, performing ultrasonic treatment at room temperature, and concentrating to remove tetrahydrofuran;
(2) cooling to room temperature, adding deionized water under ultrasonic condition, filtering, ultrafiltering, centrifuging, collecting upper layer transparent water phase solution, and freeze drying to obtain powdered solid;
(3) preparing the powdery solid obtained in the step (2) into a solution, adding RGD short peptide, and reacting;
(4) and (4) dialyzing the reaction solution obtained in the step (3) in distilled water, and freeze-drying the dialyzed solution to obtain the nano-composite.
Preferably, in the step (1), the ultrasonic treatment is performed for 5-10 min, so that the distearoyl phosphatidyl ethanolamine-polyethylene glycol-maleimide, the gastric cancer chemotherapeutic drug and the indocyanine green are fully mixed and dispersed in tetrahydrofuran, and the mixture is concentrated to be subjected to vacuum pumping on a 70 ℃ water bath and then rotary evaporation.
Preferably, in the step (2), the ultrasonic time is 5-15 min, 20mL of deionized water is added, and the polymer is self-assembled in the ultrasonic process to coat the adriamycin and the indocyanine green to form the nano micelle particles; the aperture of the filter membrane used for filtering is 220nm, the freeze drying time is 10-20 h, and the obtained nano-composite has good dispersibility.
Preferably, in the step (3), the powdery solid obtained in the step (2) is prepared into a solution with a concentration of 2mg/mL, the reaction time of adding the RGD short peptide is 4-12 h, and the thiol of the RGD short peptide can fully react with the maleimide group on the surface of the nano-composite.
Preferably, in the step (4), the cut-off molecular weight of a dialysis bag used for dialysis is 5000D, and water is changed once every 6h during dialysis to remove free unreacted RGD short peptide.
Compared with the prior art, the invention has the beneficial effects that:
the nano-composite preparation integrates targeted gastric cancer treatment and fluorescence imaging tracing, can realize targeted aggregation on gastric cancer focus imaging, controls the release of drugs, increases the concentration of targeted site drugs and improves the action time of the drugs, and has wide application prospect in early gastric cancer targeted diagnosis and treatment and drug delivery.
Drawings
Fig. 1 is a photograph of a transmission electron microscope of the nanocomposite prepared in example 1.
Fig. 2 is a photograph of a transmission electron microscope of the nanocomposite prepared in example 2.
Fig. 3 is a photograph of a transmission electron microscope of the nanocomposite prepared in example 3.
Fig. 4 is a photograph of a transmission electron microscope of the nanocomposite prepared in example 4.
Fig. 5 is a transmission electron micrograph of the nanocomposite prepared in comparative example 1.
Fig. 6 is a transmission electron micrograph of the nanocomposite prepared in comparative example 2.
Fig. 7 shows ICG loading and encapsulation efficiencies in the nanocomposites of example 1, example 2, and comparative example 3.
Fig. 8 shows the drug loading and encapsulation efficiencies of doxorubicin in the nanocomposites of example 1, example 2 and comparative example 3.
Fig. 9 is a confocal laser image in effect example 1.
Fig. 10 is a graph showing the growth of tumor volume in effect example 2.
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples. It will be understood by those skilled in the art that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
In the examples, the experimental methods used were, unless otherwise specified, conventional methods, and materials, reagents, etc., used were, unless otherwise specified, commercially available, wherein the RGD short peptide was obtained from Shanghai Chu peptide Biotech, Inc., and the amino acid sequence thereof was Arg-Gly-Asp. The molecular weight of the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide selected below is 2805.5.
Example 1
One embodiment of the nanocomposite of the present invention, a method of making the same, comprises the steps of:
(1) weighing 1 part of indocyanine green by weight, adding 5mL of tetrahydrofuran, mixing the mixture with 5 parts of distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide by weight and 0.5 part of adriamycin by weight, performing ultrasonic treatment at room temperature for 10min to fully disperse and dissolve the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide, the indocyanine green and the adriamycin, mixing, placing the round-bottomed flask on a rotary evaporator, performing water bath at 70 ℃, vacuumizing, and performing rotary evaporation; when the organic solvent is completely evaporated, the nanostructure is successfully transferred from the oil phase to the water phase;
(2) after the mixture is cooled to room temperature, the ultrasonic probe acts for 15min to disperse the mixture; filtering with a 220nm filter membrane, ultrafiltering and centrifuging, removing bottom precipitate, collecting upper layer transparent water phase nano-structured solution, and freeze drying for 20 hr to obtain powdery solid;
(3) preparing 2.5mL of micellar solution with the concentration of 2mg/mL from the powdery solid obtained in the step (2), adding one part per million of RGD short peptide in weight components, and reacting for 12 h;
(4) dialyzing in distilled water by using a 5000D dialysis bag to remove free RGD short peptide, and changing water once within 6 h; and (3) freeze-drying the micelle aqueous solution to obtain the nano-composite.
The particle size distribution of the nanocomposite of this example was measured by a dynamic laser light scattering apparatus, and fig. 1 is a transmission electron micrograph of the integrated preparation for diagnosis and treatment of this example. As is clear from FIG. 1, the average particle size in this example is 122nm, the particles are spherical, the polydispersity is 0.125, and the dispersion is relatively uniform.
Example 2
One embodiment of the nanocomposite of the present invention, a method of making the same, comprises the steps of:
(1) weighing 5 parts of indocyanine green by weight, adding 5mL of tetrahydrofuran, mixing the mixture with 20 parts of distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide by weight and 1 part of adriamycin by weight, performing ultrasonic treatment for 10min at room temperature to fully disperse and dissolve the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide, the indocyanine green and the adriamycin, mixing, placing a round-bottomed flask on a rotary evaporator, performing water bath at 70 ℃, vacuumizing, and performing rotary evaporation; when the organic solvent is completely evaporated, the nanostructure is successfully transferred from the oil phase to the water phase;
(2) after the mixture is cooled to room temperature, the ultrasonic probe acts for 15min to disperse the mixture; filtering with a 220nm filter membrane, ultrafiltering and centrifuging, removing bottom precipitate, collecting upper layer transparent water phase nano-structured solution, and freeze drying for 20 hr to obtain powdery solid;
(3) preparing 2.5mL of micellar solution with the concentration of 2mg/mL from the powdery solid obtained in the step (2), adding one part of RGD short peptide which is one hundred ten thousand parts by weight, and reacting for 12 hours;
(4) dialyzing in distilled water by using a 5000D dialysis bag to remove free RGD short peptide, and changing water once within 6 h; and (3) freeze-drying the micelle aqueous solution to obtain the nano-composite.
The particle size distribution of the nanocomposite of this example was measured using a dynamic laser light scattering apparatus, and fig. 2 is a transmission electron micrograph of the integrated preparation for diagnosis and treatment of this example. As is clear from FIG. 2, the average particle diameter in this example was 134nm, the particles were spherical, the polydispersity was 0.104, and the dispersion was relatively uniform.
Example 3
One embodiment of the nanocomposite of the present invention, a method of making the same, comprises the steps of:
(1) weighing indocyanine green with the weight component of 2 parts, adding 5mL of tetrahydrofuran, mixing the mixture with distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide with the weight component of 10 parts and adriamycin with the weight component of 0.6 part, performing ultrasonic treatment for 10min at room temperature to fully disperse and dissolve the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide, the indocyanine green and the adriamycin, mixing, placing a round-bottomed flask on a rotary evaporator, performing water bath at 70 ℃, vacuumizing, and performing rotary evaporation; when the organic solvent is completely evaporated, the nanostructure is successfully transferred from the oil phase to the water phase;
(2) after the mixture is cooled to room temperature, the ultrasonic probe acts for 15min to disperse the mixture; filtering with a 220nm filter membrane, ultrafiltering and centrifuging, removing bottom precipitate, collecting upper layer transparent water phase nano-structured solution, and freeze drying for 20 hr to obtain powdery solid;
(3) preparing 2.5mL of micellar solution with the concentration of 2mg/mL from the powdery solid obtained in the step (2), adding one part of RGD short peptide of twenty-ten-thousandth of weight component, and reacting for 12 h;
(4) dialyzing in distilled water by using a 5000D dialysis bag to remove free RGD short peptide, and changing water once within 6 h; and (3) freeze-drying the micelle aqueous solution to obtain the nano-composite. As is clear from FIG. 3, the average particle size in this example was 128nm, the particles were spherical, the polydispersity was 0.124, and the dispersion was relatively uniform.
Example 4
One embodiment of the nanocomposite of the present invention, a method of making the same, comprises the steps of:
(1) weighing indocyanine green with the weight component of 2 parts, adding 5mL of tetrahydrofuran, mixing the mixture with distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide with the weight component of 10 parts and adriamycin with the weight component of 0.6 part, performing ultrasonic treatment for 5min at room temperature to fully disperse and dissolve the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide, the indocyanine green and the adriamycin, mixing, placing a round-bottomed flask on a rotary evaporator, performing water bath at 50 ℃, vacuumizing, and performing rotary evaporation; when the organic solvent is completely evaporated, the nanostructure is successfully transferred from the oil phase to the water phase;
(2) after the mixture is cooled to room temperature, the ultrasonic probe acts for 5min to disperse the mixture; filtering with a 220nm filter membrane, ultrafiltering and centrifuging, removing bottom precipitate, collecting upper layer transparent water phase nano-structured solution, and freeze drying for 10 hr to obtain powdery solid;
(3) preparing 2.5mL of micellar solution with the concentration of 2mg/mL from the powdery solid obtained in the step (2), adding one part of RGD short peptide of twenty-ten-thousandth of weight component, and reacting for 12 h;
(4) dialyzing in distilled water by using a 5000D dialysis bag to remove free RGD short peptide, and changing water once within 6 h; and (3) freeze-drying the micelle aqueous solution to obtain the nano-composite. As is clear from FIG. 4, the average particle diameter in this example is 143nm, the particles are spherical, the polydispersity is 0.247, and the dispersion is relatively uniform.
Comparative example 1
The preparation method of the nanocomposite of the present comparative example includes the steps of:
(1) weighing indocyanine green with the weight component of 1 part, adding 5mL of tetrahydrofuran, mixing the mixture with distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide with the weight component of 5 parts, performing ultrasonic treatment for 10min at room temperature to fully disperse and dissolve the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide and the indocyanine green, mixing, placing a round-bottomed flask on a rotary evaporator, performing water bath at 70 ℃, vacuumizing, and performing rotary evaporation; when the organic solvent is completely evaporated, the nanostructure is successfully transferred from the oil phase to the water phase;
(2) after the mixture is cooled to room temperature, the ultrasonic probe acts for 15min to disperse the mixture; filtering with a 220nm filter membrane, ultrafiltering, centrifuging, removing bottom precipitate, collecting upper layer transparent water phase nano-structured solution, and freeze drying for 20 hr to obtain powdered solid.
The particle size distribution of the nanocomposite of the comparative example was measured using a dynamic laser light scattering apparatus, and fig. 5 is a transmission electron micrograph of the formulation of the comparative example. As is clear from FIG. 5, the average particle diameter was 102nm, the particles were spherical, the polydispersity was 0.128, and the dispersion was relatively uniform.
Comparative example 2
The preparation method of the nanocomposite of the present comparative example includes the steps of:
(1) weighing indocyanine green of 1 part by weight and adriamycin of 0.5 part by weight, adding 5mL of tetrahydrofuran, mixing the mixture with distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide of 5 parts by weight, performing ultrasonic treatment for 10min at room temperature to fully disperse and dissolve the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide, the indocyanine green and the adriamycin, placing the round-bottomed flask on a rotary evaporator after mixing, performing water bath at 70 ℃, vacuumizing, and performing rotary evaporation; when the organic solvent is completely evaporated, the nanostructure is successfully transferred from the oil phase to the water phase;
(2) after the mixture is cooled to room temperature, the ultrasonic probe acts for 15min to disperse the mixture; filtering with a 220nm filter membrane, ultrafiltering, centrifuging, removing bottom precipitate, collecting upper layer transparent water phase nano-structured solution, and freeze drying for 20 hr to obtain powdered solid.
The particle size distribution of the nanocomposite of the comparative example was measured using a dynamic laser light scattering apparatus, and fig. 6 is a transmission electron micrograph of the formulation of the comparative example. As can be seen from FIG. 6, the average particle diameter was 134nm, the particles were spherical, the polydispersity was 0.135, and the dispersion was relatively uniform.
Comparative example 3
The preparation method of the nanocomposite of the present comparative example includes the steps of:
(1) weighing indocyanine green with the weight component of 0.5 part, adding 5mL of tetrahydrofuran, mixing the mixture with distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide with the weight component of 25 parts and adriamycin with the weight component of 1.5 parts, performing ultrasonic treatment at room temperature for 10min to fully disperse and dissolve the distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000-maleimide, the indocyanine green and the adriamycin, placing the round-bottomed flask on a rotary evaporator after mixing, performing water bath at 70 ℃, vacuumizing, and performing rotary evaporation; when the organic solvent is completely evaporated, the nanostructure is successfully transferred from the oil phase to the water phase;
(2) after the mixture is cooled to room temperature, the ultrasonic probe acts for 15min to disperse the mixture; filtering with a 220nm filter membrane, ultrafiltering and centrifuging, removing bottom precipitate, collecting upper layer transparent water phase nano-structured solution, and freeze drying for 20 hr to obtain powdery solid;
(3) preparing 2.5mL of micellar solution with the concentration of 2mg/mL from the powdery solid obtained in the step (2), adding two parts by weight of RGD short peptide into the micellar solution, and reacting for 12 hours;
(4) dialyzing in distilled water by using a 5000D dialysis bag to remove free RGD short peptide, and changing water once within 6 h; and (3) freeze-drying the micelle aqueous solution to obtain the nano-composite.
Effect example 1 comparison of ICG and Adriamycin entrapment Effect in nanocomposites of example 1, example 2 and comparative example 3
Scanning indocyanine green and adriamycin with different concentrations dissolved in DMSO by using a UV-Vis spectrophotometer, wherein the wavelength range is 550-950 nm, and taking the absorbance of the maximum absorption peak as a standard curve. The sample solutions of example 1, example 2 and comparative example 3, in which DMSO was dissolved, were subjected to UV spectrum scanning using a UV-Vis spectrophotometer to measure absorbance values at the maximum absorption peak thereof.
Calculating the concentration of the sample solution through a standard curve, and further calculating the drug loading rate and the encapsulation rate
Drug loading rate is the mass of drug contained in the carrier/total mass of drug carrier
The encapsulation rate is the mass of the drug contained in the carrier/the total mass of the fed drug
As shown in fig. 7 and 8, the drug loading rates of ICG in the nanocomposites of example 1, example 2 and comparative example 3 were 13.1%, 16.8% and 1.30%, respectively, and the encapsulation rates were 85.0%, 87.5% and 70.2%, respectively. Thus, the encapsulation effect of the nanocomposites of example 1 and example 2 on ICG is better than that of comparative example 3
Effect example 2 in vitro fluorescence imaging Effect of the nanocomposites of example 1 and comparative example 1
Will be 1 × 105SGC7901 cells are paved in a 30mm confocal special dish, after the cells are adhered to the wall at night, targeted and non-targeted nano drug-loaded materials are diluted to 30 mu g/mL (calculated by ICG content) by a DMEM medium, and are incubated with the cells for 12 hours at 37 ℃. After three washes with PBS, fixation was performed with 4% paraformaldehyde for 1 h. After 3 times of PBS washing, DAPI light-resistant staining is carried out for 2min, PBS is used for full washing for 3 times, quenching inhibitor is dripped into a bottom glass of the dish, and a cover glass is covered and mounted. Finally, the cells are placed under a laser confocal microscope, the fluorescence of cell nucleus and ICG is respectively observed by exciting light of 365nm and 633nm, and the recombination of the cells to the nano-particles is recordedThe cell uptake of the substance is shown in the confocal image in FIG. 9.
As can be seen from fig. 9, CLSM can not only qualitatively determine the uptake of the nanocomplex into the cell, but also clearly define the intracellular distribution of the nanoparticles that have entered the cell. Since DAPI localizes the nucleus (blue in the figure) and the whole cell is localized by Bright Field (Bright Field in the figure), the specific distribution of ICG in the cell is clarified by comparing ICG (red in the figure) with the coinciding region of DAPI in blue and Bright Field (large in the figure). The fluorescence intensity of the cells of the two experimental groups is observed by a confocal microscope, and the fluorescence intensity of the red ICG in the cytoplasm of the cells incubated by the targeting nano-composite (example 1) is obviously higher than that of the cells incubated by the non-targeting nano-composite (comparative example 1), so that the fluorescence developing function is good.
Effect example 3 therapeutic effects of the nanocomposites of example 2 and comparative example 2
BALB/c nude mice female (6 weeks old, 18-20g) all animal experimental processes were approved by the ethical committee of experimental animals, and were in line with the welfare requirements of experimental animals. Constructing a tumor model: subcutaneously implanting 3 × 10 SGC7901 cells into the upper right lower limb of each nude mouse; after 2 weeks of injection, nude mice subcutaneous transplantation tumor models with low permeability were obtained by screening. Tumor volume V ═ a × b2And/2, wherein a is the major diameter of the tumor and b is the minor diameter of the tumor. Nude mice bearing tumor were randomly divided into 3 groups of 5 mice each; groups 3 of nude mice were injected intravenously with PBS, no targeting nanocomplex (comparative example 2) and targeting nanocomplex (example 2), respectively; changes of tumor volume and body weight of nude mice in future 2 weeks are tracked and recorded
The curative effect of the targeting nano-composite on the tumor is further verified through a living tumor inhibition experiment. As can be seen from fig. 10, tumors receiving the targeted nanocomplex (example 2) showed significant tumor suppression effect compared to the non-targeted nanocomplex (comparative example 2) and PBS blank control group.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. The nano-composite for early diagnosis and treatment of gastric cancer is characterized by having a core-shell structure formed by an amphiphilic copolymer, wherein an inner core layer is formed by distearoyl phosphatidyl ethanolamine segments, an outer shell layer is formed by polyethylene glycol segments, near-indocyanine green and hydrophobic gastric cancer chemotherapy drugs are wrapped in the inner core layer, and the surface of the outer shell layer is connected with RGD short peptide.
2. The nanocomposite for the early diagnosis and treatment of gastric cancer according to claim 1, wherein the amphiphilic copolymer is distearoylphosphatidylethanolamine-polyethylene glycol-maleimide, preferably distearoylphosphatidylethanolamine-polyethylene glycol 2000-maleimide; the hydrophobic gastric cancer chemotherapeutic drug comprises at least one of adriamycin, 5-fluorouracil, paclitaxel and cisplatin.
3. The nanocomposite for early diagnosis and treatment of gastric cancer according to claim 2, comprising the following components in parts by weight: 5-20 parts of distearoyl phosphatidyl ethanolamine-polyethylene glycol-maleimide, 1-5 parts of indocyanine green, 0.5-1 part of hydrophobic gastric cancer chemotherapy drug and one part per million to one hundred thousand parts of RGD oligopeptide.
4. The nanocomposite for early diagnosis and treatment of gastric cancer according to any one of claims 1 to 3, wherein the particle size of the nanocomposite is 50 to 200 nm.
5. The nanocomposite for early diagnosis and treatment of gastric cancer according to claim 4, wherein the amino acid sequence of the RGD short peptide is Arg-Gly-Asp.
6. The method for preparing a nano-composite for the early diagnosis and treatment of gastric cancer according to any one of claims 1 to 5, comprising the steps of:
(1) adding indocyanine green into tetrahydrofuran, adding distearoyl phosphatidyl ethanolamine-polyethylene glycol-maleimide and hydrophobic gastric cancer chemotherapeutic drugs, mixing, performing ultrasonic treatment at room temperature, and concentrating to remove tetrahydrofuran;
(2) cooling to room temperature, adding deionized water under ultrasonic condition, filtering, ultrafiltering, centrifuging, collecting upper layer transparent water phase solution, and freeze drying to obtain powdered solid;
(3) preparing the powdery solid obtained in the step (2) into a solution, adding RGD short peptide, and reacting;
(4) and (4) dialyzing the reaction solution obtained in the step (3) in distilled water, and freeze-drying the dialyzed solution to obtain the nano-composite.
7. The method for preparing a nano-composite for early diagnosis and treatment of gastric cancer according to claim 6, wherein in the step (1), the ultrasonic time is 5-10 min, and the nano-composite is concentrated to be subjected to rotary evaporation after water bath vacuum pumping at 50-70 ℃.
8. The method for preparing a nano-composite for early diagnosis and treatment of gastric cancer as claimed in claim 6, wherein in the step (2), the ultrasound time is 5-15 min, the pore diameter of the filter membrane used for filtering is 220nm, and the freeze-drying time is 10-20 h.
9. The method of claim 6, wherein in the step (3), the powdered solid obtained in the step (2) is prepared into a solution with a concentration of 2mg/mL, and the reaction time for adding the RGD short peptide is 4-12 h.
10. The method for preparing nano-composite for early diagnosis and treatment of gastric cancer according to claim 6, wherein in the step (4), the cut-off molecular weight of the dialysis bag used for dialysis is 5000D, and water is changed every 6h during dialysis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010098157.8A CN111135314A (en) | 2020-02-17 | 2020-02-17 | Nano-composite for early diagnosis and treatment of gastric cancer and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010098157.8A CN111135314A (en) | 2020-02-17 | 2020-02-17 | Nano-composite for early diagnosis and treatment of gastric cancer and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111135314A true CN111135314A (en) | 2020-05-12 |
Family
ID=70527568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010098157.8A Pending CN111135314A (en) | 2020-02-17 | 2020-02-17 | Nano-composite for early diagnosis and treatment of gastric cancer and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111135314A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113827742A (en) * | 2021-09-26 | 2021-12-24 | 厦门大学附属翔安医院 | Breast cancer sentinel lymph node tracing targeting molecular probe and preparation method thereof |
| CN114246955A (en) * | 2021-12-22 | 2022-03-29 | 中山大学附属第三医院（中山大学肝脏病医院） | Nanoparticle and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012032524A1 (en) * | 2010-09-09 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Near infrared fluorescent particles and uses thereof |
| CN103861123A (en) * | 2012-12-17 | 2014-06-18 | 中国科学院深圳先进技术研究院 | Diagnosis-treatment integrated nanometer material, diagnosis-treatment integrated nanometer preparation and preparation method of nanometer preparation |
| CN108354901A (en) * | 2018-05-21 | 2018-08-03 | 中国医学科学院生物医学工程研究所 | For chemotherapy of tumors and the pH/ of photo-thermal combination therapy reduction Dual Sensitive multifunctional nano micellas and its application |
| CN109395093A (en) * | 2018-12-29 | 2019-03-01 | 广州创赛生物医用材料有限公司 | A kind of diagnosis and treatment integration preparation and preparation method thereof for Alzheimer disease |
| CN109481700A (en) * | 2018-12-29 | 2019-03-19 | 广州贝奥吉因生物科技有限公司 | A kind of molecular probe and preparation method thereof for hepatocarcinoma early diagnosis |
-
2020
- 2020-02-17 CN CN202010098157.8A patent/CN111135314A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012032524A1 (en) * | 2010-09-09 | 2012-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd | Near infrared fluorescent particles and uses thereof |
| CN103861123A (en) * | 2012-12-17 | 2014-06-18 | 中国科学院深圳先进技术研究院 | Diagnosis-treatment integrated nanometer material, diagnosis-treatment integrated nanometer preparation and preparation method of nanometer preparation |
| CN108354901A (en) * | 2018-05-21 | 2018-08-03 | 中国医学科学院生物医学工程研究所 | For chemotherapy of tumors and the pH/ of photo-thermal combination therapy reduction Dual Sensitive multifunctional nano micellas and its application |
| CN109395093A (en) * | 2018-12-29 | 2019-03-01 | 广州创赛生物医用材料有限公司 | A kind of diagnosis and treatment integration preparation and preparation method thereof for Alzheimer disease |
| CN109481700A (en) * | 2018-12-29 | 2019-03-19 | 广州贝奥吉因生物科技有限公司 | A kind of molecular probe and preparation method thereof for hepatocarcinoma early diagnosis |
Non-Patent Citations (3)
| Title |
|---|
| JIE DING ET AL: ""Targeting effect of PEGylated liposomes modified with the Arg-Gly-Asp sequence on gastric cancer"", 《ONCOLOGY REPORTS》 * |
| 孟翔峰 主编: "《简明口腔生物材料研究》", 30 November 2019 * |
| 金青哲 主编: "《功能性脂质》", 31 August 2013, 北京：中国轻工业出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113827742A (en) * | 2021-09-26 | 2021-12-24 | 厦门大学附属翔安医院 | Breast cancer sentinel lymph node tracing targeting molecular probe and preparation method thereof |
| CN114246955A (en) * | 2021-12-22 | 2022-03-29 | 中山大学附属第三医院（中山大学肝脏病医院） | Nanoparticle and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112121029B (en) | Bionic dopamine polymerization drug-loaded nano delivery system and preparation method thereof | |
| Hwang et al. | Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles | |
| CN102740895B (en) | Nanoconjugate and nanoconjugate preparation | |
| JP6049854B2 (en) | Substance-encapsulating vesicle and method for producing the same | |
| CN110237035B (en) | Active targeting amphiphilic polypeptide nano-drug carrier and preparation and application thereof | |
| KR101228106B1 (en) | Nanocarriers with Enhanced Skin Permeability, Cellular Uptake and Tumor Targeting | |
| CN102327230B (en) | Protein nanometer granules wrapped with taxane medicaments and preparation method for nanometer granules | |
| EP1583473A2 (en) | Nanoparticle based stabilization of ir fluorescent dyes | |
| Yang et al. | Tumor-targeted/reduction-triggered composite multifunctional nanoparticles for breast cancer chemo-photothermal combinational therapy | |
| US10786465B2 (en) | Polymer/copolymer nanoparticles conjugated to gambogic acid | |
| US20100209353A1 (en) | Tumor targeting protein conjugate and a method for preparing the same | |
| CN113952463B (en) | Nanometer diagnosis and treatment agent and preparation method and application thereof | |
| CN112402626B (en) | Tumor-targeted bio-camouflage nano drug delivery system and preparation method thereof | |
| CN102357077B (en) | Protein nanometer particle for wrapping slightly soluble medicines and preparation method thereof | |
| Son et al. | Ultrasmall gold nanosatellite-bearing transformable hybrid nanoparticles for deep tumor penetration | |
| CN111450252B (en) | Medicine for targeted blocking of tumor blood vessels and preparation method and application thereof | |
| CN111135314A (en) | Nano-composite for early diagnosis and treatment of gastric cancer and preparation method thereof | |
| CN104814934A (en) | Herceptin modified paclitaxel-carried targeting nanoparticle transfer system | |
| Fan et al. | Lignin-assisted construction of sub-10 nm supramolecular self-assembly for photothermal immunotherapy and potentiating anti-PD-1 therapy against primary and distant breast tumors | |
| Xiao et al. | The passive targeting of polymeric micelles in various types and sizes of tumor models | |
| CN112587502B (en) | Erythrocyte membrane coated MOFs nano-drug carrier and preparation method and application thereof | |
| CN114081953A (en) | Prodrug dendrimer nano-carrier and preparation method and application thereof | |
| CN112156066B (en) | Preparation method of injectable composite hydrogel double-drug-loading system containing micelle | |
| CN108186571A (en) | Reversible crosslink asymmetry vesica is preparing the application in treating acute leukemia drug | |
| CN102357076B (en) | Preparation method of protein nanoparticles coating insoluble drug |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200512 |